Validation and characterization of a novel peptide that binds monomeric and aggregated β-amyloid and inhibits the formation of neurotoxic oligomers

Renae K. Barr, Giuseppe Verdile, Linda K. Wijaya, Michael Morici, Kevin Taddei, Veer B. Gupta, Steve Pedrini, Liang Jin, Joseph A. Nicolazzo, Erin Knock, Paul E. Fraser, Ralph N. Martins

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Although the formation of β-amyloid (Aβ) deposits in the brain is a hallmark of Alzheimer disease (AD), the soluble oligomers rather than the mature amyloid fibrils most likely contribute to Aβ toxicity and neurodegeneration. Thus, the discovery of agents targeting soluble Aβ oligomers is highly desirable for early diagnosis prior to the manifestation of a clinical AD phenotype and also more effective therapies. We have previously reported that a novel 15-amino acid peptide (15-mer), isolated via phage display screening, targeted Aβ and attenuated its neurotoxicity (Taddei, K., Laws, S. M., Verdile, G., Munns, S., D'Costa, K., Harvey, A. R., Martins, I. J., Hill, F., Levy, E., Shaw, J. E., and Martins, R. N. (2010) Neurobiol. Aging 31, 203-214). The aim of the current study was to generate and biochemically characterize analogues of this peptide with improved stability and therapeutic potential. We demonstrated that a stable analogue of the 15-amino acid peptide (15M S.A.) retained the activity and potency of the parent peptide and demonstrated improved proteolytic resistance in vitro (stable to t = 300 min, c.f. t = 30 min for the parent peptide). This candidate reduced the formation of soluble Aβ42 oligomers, with the concurrent generation of non-toxic, insoluble aggregates measuring up to 25-30 nm diameter as determined by atomic force microscopy. The 15M S.A. candidate directly interacted with oligomeric Aβ42, as shown by coimmunoprecipitation and surface plasmon resonance/Biacore analysis, with an affinity in the low micromolar range. Furthermore, this peptide bound fibrillar Aβ42 and also stained plaques ex vivo in brain tissue from AD model mice. Given its multifaceted ability to target monomeric and aggregated Aβ42 species, this candidate holds promise for novel preclinical AD imaging and therapeutic strategies.

Original languageEnglish
Pages (from-to)547-559
Number of pages13
JournalJournal of Biological Chemistry
Volume291
Issue number2
DOIs
Publication statusPublished - 8 Jan 2016

Cite this

Barr, Renae K. ; Verdile, Giuseppe ; Wijaya, Linda K. ; Morici, Michael ; Taddei, Kevin ; Gupta, Veer B. ; Pedrini, Steve ; Jin, Liang ; Nicolazzo, Joseph A. ; Knock, Erin ; Fraser, Paul E. ; Martins, Ralph N. / Validation and characterization of a novel peptide that binds monomeric and aggregated β-amyloid and inhibits the formation of neurotoxic oligomers. In: Journal of Biological Chemistry. 2016 ; Vol. 291, No. 2. pp. 547-559.
@article{b4c163b328ab46bcbf35fb118a55f652,
title = "Validation and characterization of a novel peptide that binds monomeric and aggregated β-amyloid and inhibits the formation of neurotoxic oligomers",
abstract = "Although the formation of β-amyloid (Aβ) deposits in the brain is a hallmark of Alzheimer disease (AD), the soluble oligomers rather than the mature amyloid fibrils most likely contribute to Aβ toxicity and neurodegeneration. Thus, the discovery of agents targeting soluble Aβ oligomers is highly desirable for early diagnosis prior to the manifestation of a clinical AD phenotype and also more effective therapies. We have previously reported that a novel 15-amino acid peptide (15-mer), isolated via phage display screening, targeted Aβ and attenuated its neurotoxicity (Taddei, K., Laws, S. M., Verdile, G., Munns, S., D'Costa, K., Harvey, A. R., Martins, I. J., Hill, F., Levy, E., Shaw, J. E., and Martins, R. N. (2010) Neurobiol. Aging 31, 203-214). The aim of the current study was to generate and biochemically characterize analogues of this peptide with improved stability and therapeutic potential. We demonstrated that a stable analogue of the 15-amino acid peptide (15M S.A.) retained the activity and potency of the parent peptide and demonstrated improved proteolytic resistance in vitro (stable to t = 300 min, c.f. t = 30 min for the parent peptide). This candidate reduced the formation of soluble Aβ42 oligomers, with the concurrent generation of non-toxic, insoluble aggregates measuring up to 25-30 nm diameter as determined by atomic force microscopy. The 15M S.A. candidate directly interacted with oligomeric Aβ42, as shown by coimmunoprecipitation and surface plasmon resonance/Biacore analysis, with an affinity in the low micromolar range. Furthermore, this peptide bound fibrillar Aβ42 and also stained plaques ex vivo in brain tissue from AD model mice. Given its multifaceted ability to target monomeric and aggregated Aβ42 species, this candidate holds promise for novel preclinical AD imaging and therapeutic strategies.",
author = "Barr, {Renae K.} and Giuseppe Verdile and Wijaya, {Linda K.} and Michael Morici and Kevin Taddei and Gupta, {Veer B.} and Steve Pedrini and Liang Jin and Nicolazzo, {Joseph A.} and Erin Knock and Fraser, {Paul E.} and Martins, {Ralph N.}",
year = "2016",
month = "1",
day = "8",
doi = "10.1074/jbc.M115.679993",
language = "English",
volume = "291",
pages = "547--559",
journal = "Journal of Biological Chemistry",
issn = "1083-351X",
publisher = "American Society for Biochemistry and Molecular Biology",
number = "2",

}

Validation and characterization of a novel peptide that binds monomeric and aggregated β-amyloid and inhibits the formation of neurotoxic oligomers. / Barr, Renae K.; Verdile, Giuseppe; Wijaya, Linda K.; Morici, Michael; Taddei, Kevin; Gupta, Veer B.; Pedrini, Steve; Jin, Liang; Nicolazzo, Joseph A.; Knock, Erin; Fraser, Paul E.; Martins, Ralph N.

In: Journal of Biological Chemistry, Vol. 291, No. 2, 08.01.2016, p. 547-559.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Validation and characterization of a novel peptide that binds monomeric and aggregated β-amyloid and inhibits the formation of neurotoxic oligomers

AU - Barr, Renae K.

AU - Verdile, Giuseppe

AU - Wijaya, Linda K.

AU - Morici, Michael

AU - Taddei, Kevin

AU - Gupta, Veer B.

AU - Pedrini, Steve

AU - Jin, Liang

AU - Nicolazzo, Joseph A.

AU - Knock, Erin

AU - Fraser, Paul E.

AU - Martins, Ralph N.

PY - 2016/1/8

Y1 - 2016/1/8

N2 - Although the formation of β-amyloid (Aβ) deposits in the brain is a hallmark of Alzheimer disease (AD), the soluble oligomers rather than the mature amyloid fibrils most likely contribute to Aβ toxicity and neurodegeneration. Thus, the discovery of agents targeting soluble Aβ oligomers is highly desirable for early diagnosis prior to the manifestation of a clinical AD phenotype and also more effective therapies. We have previously reported that a novel 15-amino acid peptide (15-mer), isolated via phage display screening, targeted Aβ and attenuated its neurotoxicity (Taddei, K., Laws, S. M., Verdile, G., Munns, S., D'Costa, K., Harvey, A. R., Martins, I. J., Hill, F., Levy, E., Shaw, J. E., and Martins, R. N. (2010) Neurobiol. Aging 31, 203-214). The aim of the current study was to generate and biochemically characterize analogues of this peptide with improved stability and therapeutic potential. We demonstrated that a stable analogue of the 15-amino acid peptide (15M S.A.) retained the activity and potency of the parent peptide and demonstrated improved proteolytic resistance in vitro (stable to t = 300 min, c.f. t = 30 min for the parent peptide). This candidate reduced the formation of soluble Aβ42 oligomers, with the concurrent generation of non-toxic, insoluble aggregates measuring up to 25-30 nm diameter as determined by atomic force microscopy. The 15M S.A. candidate directly interacted with oligomeric Aβ42, as shown by coimmunoprecipitation and surface plasmon resonance/Biacore analysis, with an affinity in the low micromolar range. Furthermore, this peptide bound fibrillar Aβ42 and also stained plaques ex vivo in brain tissue from AD model mice. Given its multifaceted ability to target monomeric and aggregated Aβ42 species, this candidate holds promise for novel preclinical AD imaging and therapeutic strategies.

AB - Although the formation of β-amyloid (Aβ) deposits in the brain is a hallmark of Alzheimer disease (AD), the soluble oligomers rather than the mature amyloid fibrils most likely contribute to Aβ toxicity and neurodegeneration. Thus, the discovery of agents targeting soluble Aβ oligomers is highly desirable for early diagnosis prior to the manifestation of a clinical AD phenotype and also more effective therapies. We have previously reported that a novel 15-amino acid peptide (15-mer), isolated via phage display screening, targeted Aβ and attenuated its neurotoxicity (Taddei, K., Laws, S. M., Verdile, G., Munns, S., D'Costa, K., Harvey, A. R., Martins, I. J., Hill, F., Levy, E., Shaw, J. E., and Martins, R. N. (2010) Neurobiol. Aging 31, 203-214). The aim of the current study was to generate and biochemically characterize analogues of this peptide with improved stability and therapeutic potential. We demonstrated that a stable analogue of the 15-amino acid peptide (15M S.A.) retained the activity and potency of the parent peptide and demonstrated improved proteolytic resistance in vitro (stable to t = 300 min, c.f. t = 30 min for the parent peptide). This candidate reduced the formation of soluble Aβ42 oligomers, with the concurrent generation of non-toxic, insoluble aggregates measuring up to 25-30 nm diameter as determined by atomic force microscopy. The 15M S.A. candidate directly interacted with oligomeric Aβ42, as shown by coimmunoprecipitation and surface plasmon resonance/Biacore analysis, with an affinity in the low micromolar range. Furthermore, this peptide bound fibrillar Aβ42 and also stained plaques ex vivo in brain tissue from AD model mice. Given its multifaceted ability to target monomeric and aggregated Aβ42 species, this candidate holds promise for novel preclinical AD imaging and therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=84954107115&partnerID=8YFLogxK

U2 - 10.1074/jbc.M115.679993

DO - 10.1074/jbc.M115.679993

M3 - Article

VL - 291

SP - 547

EP - 559

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 1083-351X

IS - 2

ER -